Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Recombinant DNA Technology Market In The Coming Years?

In recent times, the recombinant DNA technology market has experienced significant growth. Projected to increase from $858.94 billion in 2024 to $913.42 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%, this market’s upward trend is mainly due to factors like healthcare needs, expansion of the biopharmaceutical industry, increased R&D investments, and the introduction of personalized medicine.

In the coming years, the recombinant DNA technology market is projected to experience significant expansion. The market is set to increase to $1299.96 billion by 2029, with a compound annual growth rate (CAGR) of 9.2%. The predicted growth during this period can be credited to the surge in chronic illnesses, and the emergence of biotech startups, increased biotech funding, global expansion of biotech markets, consumer endorsement and learning. Notable trends for the forecast period include improvements in scientific and gene editing technologies, progress in cell and gene treatments, advancement of RNA therapeutic practices, their therapeutic uses in uncommon diseases, and the integration of Artificial Intelligence and data.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Recombinant DNA Technology Market?

The surge in chronic illnesses is projected to fuel the expansion of the recombinant DNA technology market. Chronic conditions, referred to as diseases that persist for a year or more and require constant medical attention, limit daily activities, or both. Recombinant DNA technology has revolutionized healthcare by generating biopharmaceutical proteins utilized in pharmaceuticals, and through gene therapy, which replaces faulty genes with healthy ones, aiming to cure diseases. For example, the World Health Organization, a Switzerland-based intergovernmental entity, predicted in February 2024 that over 35 million new cancer cases are anticipated by 2050, marking a 77% growth in comparison to the projected 20 million instances in 2022. Thus, the rise in chronic ailments is fueling the expansion of the recombinant DNA technology market.

Which Sub-Segments Are Driving Growth Within The Recombinant DNA Technology Market?

The recombinant dna technologymarket covered in this report is segmented –

1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing

2) By Component Type: Expression System, Cloning Vector

3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types

4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types

Subsegments:

1) By Recombinant Protein Drugs: Hormones, Growth Factors

2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines

3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop

4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems

5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies

6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)

What Future-Focused Trends Are Anticipated In The Recombinant DNA Technology Market?

The progression of technology is a significant trend in the recombinant DNA technology market. Key companies in the space are focusing on advancing technology in an effort to maintain their market position. For example, in August 2022, the US-based biotech company Bluebird bio, Inc. launched the FDA-approved ZYNTEGLO, a one-of-a-kind gene therapy which treats beta-thalassemia by targeting its genetic root, thus potentially freeing sufferers from regular red blood cell transfusions. Using an ex-vivo lentiviral vector to alter patient cells, it is the first gene therapy for this condition to receive FDA approval in the U.S. This development paves the way to lessen the ongoing management of beta-thalassemia.

Which Players Are Shaping The Competitive Landscape Of The Recombinant DNA Technology Market?

Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report

How Do Regional Dynamics Influence The Recombinant DNA Technology Market Performance?

North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp

Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2025, By The Business Research Company

Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Culture Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Cell Based Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model